Synthetic Data Governance: An Enterprise Deployment Framework

Synthetic data should be governed as a first-class enterprise asset held to the same standard as the real data it emulates—not treated as a shortcut around regulation. Effective synthetic data governance rests on documented generation processes, validated fitness for purpose, and clear accountability under frameworks such as the EU AI Act, ISO/IEC 42001, and sector-specific supervisory guidance.

Why synthetic data is not a compliance exit

The most consequential misconception among boards is that synthetic data automatically escapes data-protection obligations. It does not. The UK ICO’s anonymisation guidance, updated in March 2025, classifies synthetic data as a privacy-enhancing technology rather than a guaranteed exit from UK GDPR: generating synthetic data from personal data is itself processing that requires a lawful basis, and the output is only anonymous—and therefore outside GDPR scope—when re-identification risk has been reduced to a sufficiently remote level under the ‘motivated intruder’ test. In other words, the act of creation is regulated, and the status of the output must be earned through demonstrable risk reduction, not assumed.

This reframes synthetic data from a loophole into a controlled asset. The governance question is not whether the data is synthetic, but whether its provenance, generation, and residual risk are documented and defensible.

The regulatory obligations that apply directly

Where synthetic datasets feed high-risk AI systems, the EU AI Act’s Article 10 applies squarely. It mandates that training, validation, and testing datasets be relevant, representative, free of errors, and complete, and requires data governance practices addressing design choices, data collection, preparation, and bias detection and mitigation—requirements that apply equally to synthetic datasets used in those systems. Crucially, these obligations are AI-specific and apply irrespective of whether personal data is involved; where personal data is used, the GDPR’s Articles 5, 25, and 32—purpose limitation, data-protection-by-design, and security of processing—provide the concrete mechanisms through which those obligations must be implemented and verified.

Broader governance frameworks converge on the same expectations. The EU AI Act, MHRA guidance, HIPAA privacy requirements, and the NIST AI Risk Management Framework, published in January 2023, all emphasise transparency, accountability, robustness, and risk management; in practice these imply that synthetic datasets must be accompanied by clear documentation of generation processes, validation protocols, and intended use cases to support regulatory compliance.

A certifiable spine: ISO/IEC 42001

Organisations seeking an auditable operating model should anchor their programme in ISO/IEC 42001:2023, the world’s first international AI management system standard, published in December 2023. It specifies requirements for AI governance including AI-specific controls for data governance, model transparency, bias mitigation, and human oversight, providing an auditable, certifiable framework applicable to the full lifecycle of AI systems that use or generate synthetic data. Adopting it gives the board a defensible governance spine that maps cleanly onto the transparency and accountability expectations the regulators share.

Sector-specific rigour: BFSI, life sciences, and manufacturing

Generic governance is necessary but insufficient; each regulated domain imposes its own bar. In banking, the Basel Committee’s 2018 Stress Testing Principles (BCBS d450) establish that stress-test data must be accurate and sufficiently granular, that models and methodologies be fit for purpose and subject to regular challenge and review, and that governance roles—scenario development and approval, model development and validation, and the second and third lines of defence—be formally specified and approved by the board or senior management. Synthetic scenario data used in stress testing inherits these expectations wholesale.

In life sciences, the EMA’s adopted Reflection Paper on the Use of AI in the Medicinal Product Lifecycle acknowledges data augmentation, including synthetic data, as a legitimate technique to expand training datasets, but requires that sources of data and any processing activity be documented in detail to allow traceability in line with GxP requirements, and mandates active measures to minimise bias integration. Traceability, not novelty, is the operative demand.

In manufacturing, ISO 23247—the Digital Twin Framework for Manufacturing—defines a digital twin as a ‘fit for purpose digital representation of an observable manufacturing element with synchronisation between the element and its digital representation’, and provides a generic reference architecture for applications including synthetic-data-driven quality modelling across discrete, batch, and continuous processes, enabling deployment of the digital thread so that model-based engineering standards can be included in the framework.

The unresolved frontier: synthetic control populations

Leaders should deploy with clear eyes about where the rules run out. As of early 2026, no single regulatory standard or guideline fully governs synthetic clinical data; the landscape is evolving across FDA/EMA joint AI principles, the European Health Data Space framework, and the MHRA’s external control arm guidance, meaning organisations must currently rely on best practices from the literature and apply the same rigour to synthetic datasets as to real data. The gap is sharpest for synthetic ‘control’ populations: the FDA’s 2023 draft guidance on externally controlled trials defines an external control arm as data from another setting, historical or concurrent, and does not currently address whether such an arm may be composed of generative synthetic data—a material regulatory gap that applies to BFSI and clinical domains alike where synthetic control populations are used for comparative analysis.

A deployment framework in practice

Drawing these threads together, a defensible programme has four pillars. First, provenance and lawful basis: treat generation as processing, establish a lawful basis, and test residual re-identification risk against the motivated-intruder standard. Second, fitness for purpose: validate that synthetic datasets are relevant, representative, and bias-mitigated for their intended high-risk use. Third, documentation and traceability: record generation processes, validation protocols, and intended use cases to satisfy transparency and GxP-style expectations. Fourth, accountable governance: formalise roles and board oversight under a certifiable management system.

Takeaway

Synthetic data earns its place as an enterprise asset only when it is governed with the same discipline as the real data it stands in for. The frameworks already exist to do this credibly; where they fall silent—notably on synthetic control arms—prudence, documentation, and equivalent rigour remain the safest course.

Sources

• EU AI Act Article 10 – Data and Data Governance
• EU AI Act Article 10 – AI Act Service Desk (European Commission)
• Stress Testing Principles (BCBS d450, October 2018)
• BCBS Stress Testing Principles – press release
• Reflection Paper on the Use of Artificial Intelligence (AI) in the Medicinal Product Lifecycle (EMA/CHMP/CVMP/83833/2023)
• ICO Anonymisation Guidance – About this guidance
• Synthetic Data in Healthcare and Drug Development: Definitions, Regulatory Frameworks, Issues (PMC / CPT: Pharmacometrics & Systems Pharmacology)
• ISO/IEC 42001:2023 – AI Management Systems
• An Analysis of the New ISO 23247 Series of Standards on Digital Twin Framework for Manufacturing
• Critical Challenges and Guidelines in Evaluating Synthetic Tabular Data: A Systematic Review
• On the Challenges of Deploying Privacy-Preserving Synthetic Data in the Enterprise

---